This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: Guanine nucleotide exchange factors (GEF) control the rate-limiting step of physiologic RAS activation. In this issue of Cancer Discovery, Hofmann and colleagues describe the discovery of a selective inhibitor targeting the GEF, SOS1, along with its preclinical effects in suppressing KRAS-mutant tumor growth.
See related article by Hofmann et al., p. 142.
Footnotes
Cancer Discov 2021;11:17–9
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors
Jump to section
Advertisement